SCHEMBL24254502

SCHEMBL24254502

Cc1ccc(S(=O)(=O)N(C)C)cc1NC(=O)Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.66
LMNA P02545 4/20 0.66
MAPT P10636 2/20 0.66
HTT P42858 1/20 0.66
SMN1; SMN2 Q16637 1/20 0.66
KMT2A Q03164 2/20 0.56
CTSD P07339 1/20 0.55
NPSR1 Q6W5P4 2/20 0.52
THRB P10828 1/20 0.52
KCNJ6 P48051 1/20 0.52
KCNJ5 P48544 1/20 0.52
KCNJ3 P48549 1/20 0.52
MEN1 O00255 1/20 0.52
GAA P10253 1/20 0.51
RAB9A P51151 1/20 0.51
POLB P06746 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24254485 0.92 ALDH1A1 (0.60) ALDH1A1LMNAMAPTHTTSMN1; SMN2
SCHEMBL26188145 0.88 ALDH1A1 (0.64) ALDH1A1LMNAMAPTKMT2ANPSR1
SCHEMBL24254497 0.88 ALDH1A1 (0.56) ALDH1A1LMNAMAPTHTTSMN1; SMN2
SCHEMBL26188053 0.87 VCAM1 (0.57) ALDH1A1LMNAMAPTHTTSMN1; SMN2
SCHEMBL26188045 0.87 ALDH1A1 (0.57) ALDH1A1LMNAMAPTHTTSMN1; SMN2
SCHEMBL26188049 0.85 ALDH1A1 (0.64) ALDH1A1LMNAMAPTSMN1; SMN2KMT2A
SCHEMBL24254504 0.85 ALDH1A1 (0.63) ALDH1A1LMNAMAPTKMT2ANPSR1
SCHEMBL24254500 0.83 ALDH1A1 (0.78) ALDH1A1LMNAMAPTSMN1; SMN2KMT2A
SCHEMBL26188047 0.83 ALDH1A1 (0.67) ALDH1A1LMNAMAPTSMN1; SMN2KMT2A
SCHEMBL24254529 0.82 ALDH1A1 (0.53) ALDH1A1LMNAMAPTHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP1 ALDH1A1 1387/4885LMNA 3727/4885MAPT 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.